Navigation Links
GSK and Amicus Therapeutics Enter Exclusive Worldwide Agreement to Develop and Commercialize Amigal™ for Fabry Disease
Date:10/29/2010

evelopment of Amicus' candidate drug products, the timing and reporting of results from preclinical studies and clinical trials evaluating Amicus' candidate drug products and the projected cash position for the Company, including achievement of development and commercialization milestone payments and sales royalties under our collaboration with GlaxoSmithKline.  Words such as, but not limited to, "look forward to," "believe," "expect," "anticipate," "estimate," "intend," "plan," "targets," "likely," "will," "would," "should" and "could," and similar expressions or words identify forward-looking statements. Such forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties. The inclusion of forward-looking statements should not be regarded as a representation by Amicus that any of its plans will be achieved. Any or all of the forward-looking statements in this press release may turn out to be wrong. They can be affected by inaccurate assumptions Amicus might make or by known or unknown risks and uncertainties. For example, with respect to statements regarding the goals, progress, timing and outcomes of discussions with regulatory authorities and the potential goals, progress, timing and results of preclinical studies and clinical trials, actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in the business of Amicus, including, without limitation: the potential that results of clinical or pre-clinical studies indicate that the product candidates are unsafe or ineffective; the potential that it may be difficult to enroll patients in our clinical trials; the potential that regulatory authorities may not grant or may delay approval for our product candidates; the potential that preclinical and clinical studies could be delayed because we identify serious side effects or other safety issues; the potential that we will need addi
'/>"/>
SOURCE Amicus Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
2. Amicus Therapeutics Announces Plans to Present Phase 1 Data for AT2220 for Pompe Disease
3. Amicus Therapeutics Announces Positive Results From Two Phase 1 Clinical Studies of AT2220 for Pompe Disease
4. Amicus Therapeutics to Present at the 26th Annual JPMorgan Healthcare Conference
5. Amicus Therapeutics Presents Data from Clinical Ex Vivo Response Study and Phase 1 Studies of AT2220
6. Amicus Therapeutics Begins Phase 2 Clinical Trial of AT2220 in Pompe Disease
7. Amicus Therapeutics Announces Successful Completion of End of Phase 2 Meeting With FDA for Amigal in Fabry Disease
8. Amicus Therapeutics Announces Second Quarter 2008 Financial Results
9. Amicus Therapeutics Announces Positive Progress of Three Lead Clinical Programs and General Outlook for 2009
10. Amicus Therapeutics Suspends Enrollment for Phase 2 Clinical Trial of AT2220 for Pompe Disease
11. Amicus Therapeutics Announces Issuance of New Plicera(TM) Composition of Matter Patent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... 2015  Array BioPharma Inc. (NASDAQ: ARRY ... and full year of its fiscal year ended ... Executive Officer of Array, noted, "Binimetinib and encorafenib, two ... track for regulatory submissions in 2016. Additional data ... BRAF-mutant colorectal cancer further validate the value of ...
(Date:8/3/2015)... Aug. 3, 2015  Charleston Laboratories, Inc., an ... second clinical development program with a Phase 1 ... CL-H1T contains fast-dissolving promethazine and sumatriptan.  ... a treatment for migraine headache pain and migraine-induced ... patients with migraine headaches also suffer from nausea ...
(Date:8/3/2015)... FLORHAM PARK, N.J. , Aug. 3, ... met its primary and secondary endpoints in a phase ... constipation (OIC) in adult patients with chronic non-cancer pain. ... antagonist (PAMORA). This is the third Phase III trial ... endpoints. Study results showed that a 0.2 ...
Breaking Medicine Technology:Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 2Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 3Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 4Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 5Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 6Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 7Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 8Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 9Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 10Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 11Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 12Charleston Laboratories, Inc. Initiates Patient Enrollment in a Phase 1 Study of Charleston's Second Product, CL-H1T 2Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 2Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 3Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 4
... Biosafety , , , ... June 29 Remember chemistry sets, ham radio, amateur astronomy, and early ... around the world belong to the Do-It-Yourself Biology (DIYbio) community, working on everything ... treatments for diseases. , , , ...
... Ireland , June 28 Warner Chilcott plc ... IV Certification Notice from Par Pharmaceutical, Inc. ("Par").  The Paragraph IV Certification ... Application (ANDA) by Par for a generic version of the Company,s ASACOL ... , , ...
Cached Medicine Technology:Responsible Science for Do-It-Yourself Biologists 2Warner Chilcott Announces Receipt of Paragraph IV Certification Notice 2Warner Chilcott Announces Receipt of Paragraph IV Certification Notice 3
(Date:8/3/2015)... ... August 03, 2015 , ... Foot and Ankle ... new associate podiatrist, creating the largest medical practice in the Mid-Atlantic region – and ... FASMA operates 21 locations with 33 doctors. , Dr. Hetal Kathrotiya-Mago is a Maryland ...
(Date:8/3/2015)... , ... August 03, 2015 , ... Did you know ... Orange County looking for exceptional and affordable home care options which A-1 Home Care ... just a few of the credentials A-1 Home Care Agency is known ...
(Date:8/2/2015)... (PRWEB) , ... August 03, 2015 , ... A new ... of some childhood cancers. The study is led by Kenneth G. Lucas, M.D. ... University of Louisville in collaboration with colleagues at Kosair Children’s Hospital and ...
(Date:8/2/2015)... ... , ... Molecular biologists in New South Wales say a protein linked to ... posted an article on the new research. Click here to read it now. ... in tissue samples from 42 patients with peritoneal mesothelioma and found a direct correlation ...
(Date:8/1/2015)... ... August 01, 2015 , ... ... are in “a trending profession” that comprises a growing percentage of U.S. physicians, ... most. , That was one part of the message delivered by John W. ...
Breaking Medicine News(10 mins):Health News:Leading Foot and Ankle Medical Practice Adds Three New Podiatrists 2Health News:Leading Foot and Ankle Medical Practice Adds Three New Podiatrists 3Health News:Leading Foot and Ankle Medical Practice Adds Three New Podiatrists 4Health News:A-1 Home Care in Los Angeles and Orange County Honors Exceptional Office Staff 2Health News:A-1 Home Care in Los Angeles and Orange County Honors Exceptional Office Staff 3Health News:UofL Physicians Conducting Vaccine Trial for Children with Relapsed Tumors at Kosair Children’s Hospital 2Health News:Scientists Link Protein Marker with Mesothelioma Prognosis in New Study, According to Surviving Mesothelioma 2Health News:COMP-Northwest Welcomes Class of 2019 2Health News:COMP-Northwest Welcomes Class of 2019 3Health News:COMP-Northwest Welcomes Class of 2019 4Health News:COMP-Northwest Welcomes Class of 2019 5
... de Toulouse-Lautrec suffered, is a genetic disease characterized by ... into how joints are destroyed by arthritis. It is ... K which hampers osteoclasts (the cells that break down ... bone resorption and dense, brittle bones. , Cathepsin ...
... Patients Received Assistance with Drug Co-Pays, HOUSTON, Nov. ... a national oral oncology specialty pharmacy, has,exceeded the $10 ... co-pays since the launch of Care Advantage in August ... Advantage to be able to,increase patient access to oral ...
... 4 Mylan Inc. (NYSE: MYL ),today ... approval from the U.S. Food and Drug Administration ... Levetiracetam Tablets, 250 mg,500 mg and 750 mg. ... Keppra(R)., Robert J. Coury, Mylan,s Vice Chairman ...
... blood pressure experienced during pregnancy could be a woman,s ... heart disease the number one killer of Canadian ... Gynecology, Graeme Smith. , Called pre-eclampsia, this type ... of all pregnancies. , But because most practicing ...
... , , TUESDAY, Nov. 4 (HealthDay News) -- Children who live ... undernourished, a new study finds. , The same is true ... impact the most, said study author Dr. Michael Weitzman, chairman ... "We know that there are long-term consequences of food insecurity ...
... Secretary and other members of bipartisan,group of Capitol ... energy, transportation, trade, labor and employment,and tax policy, ... and grueling,Presidential campaign, one thing is certain: change ... with or regulated by the federal government,will face ...
Cached Medicine News:Health News:Genetic disorder sheds light on enzyme's role in bone metabolism 2Health News:OncologyRx Care Advantage(TM) Specialty Pharmacy Passes $10 Million Milestone in Patient Financial Assistance 2Health News:OncologyRx Care Advantage(TM) Specialty Pharmacy Passes $10 Million Milestone in Patient Financial Assistance 3Health News:Mylan Receives Final Approval for First-to-File Generic Version of Antiepileptic Keppra(R) and Launches Immediately 2Health News:Pregnancy disorder signals need to screen for heart disease 2Health News:Smokers' Homes More Likely to House Hungry Kids 2Health News:Smokers' Homes More Likely to House Hungry Kids 3Health News:Venable's 'Election Watch Group' Assesses Presidential Election's Impact on Multiple Industries 2Health News:Venable's 'Election Watch Group' Assesses Presidential Election's Impact on Multiple Industries 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: